Jason Zemansky
Stock Analyst at B of A Securities
(4.70)
# 193
Out of 4,761 analysts
34
Total ratings
69.57%
Success rate
24.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Neutral | $22 → $17 | $11.07 | +53.57% | 5 | Feb 19, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $8.25 | +251.52% | 2 | Nov 22, 2024 | |
| INSM Insmed | Maintains: Buy | $84 → $86 | $81.06 | +6.09% | 8 | Oct 9, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $16.38 | +89.26% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $1.82 | +37.36% | 5 | Jun 20, 2024 | |
| CYTK Cytokinetics | Maintains: Neutral | $70 → $60 | $50.26 | +19.38% | 3 | May 23, 2024 | |
| ALVR AlloVir | Downgrades: Underperform | $391 → $23 | $9.63 | +138.84% | 2 | Dec 26, 2023 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $9 → $10 | $1.38 | +624.64% | 4 | May 12, 2023 | |
| ALLK Allakos | Maintains: Buy | $145 → $155 | $0.29 | +54,152.71% | 2 | Dec 13, 2021 |
Arcus Biosciences
Feb 19, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $11.07
Upside: +53.57%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $8.25
Upside: +251.52%
Insmed
Oct 9, 2024
Maintains: Buy
Price Target: $84 → $86
Current: $81.06
Upside: +6.09%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $16.38
Upside: +89.26%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $1.82
Upside: +37.36%
Cytokinetics
May 23, 2024
Maintains: Neutral
Price Target: $70 → $60
Current: $50.26
Upside: +19.38%
AlloVir
Dec 26, 2023
Downgrades: Underperform
Price Target: $391 → $23
Current: $9.63
Upside: +138.84%
Werewolf Therapeutics
May 12, 2023
Maintains: Buy
Price Target: $9 → $10
Current: $1.38
Upside: +624.64%
Allakos
Dec 13, 2021
Maintains: Buy
Price Target: $145 → $155
Current: $0.29
Upside: +54,152.71%